TOPIC 372: DEVELOPMENT AND VALIDATION OF CANINE SCFVS FOR PRE-CLINICAL DEVELOPMENT OF TARGETED THERAPEUTICS

The goal of this SBIR is to provide proof of concept of Vetigenicscanine derived scFv phage display platform for rapidcost effective production of highly versatilecanine derived scFvsscFvs against CDCDand CTLAthree high valueimmunological molecules being targeted by antibody based strategies in human cancer immunotherapywill be isolatedSelected scFvs will be sequenced and binding affinities determinedThrough its collaborators at the University of Pennsylvania School of Veterinary MedicineVetigenics has access to canine cellscell lines and tissues providing an unparalleled ability to validate isolated scFvTarget specificity and functionality of isolated scFvs will be validated using standard immunological assaysTo demonstrate the versatility and broad applicability of the scFv formata lead canine CDspecific scFv will be selected and used to generatecanine CAR T cells andmonoclonal antibodiesCDspecific scFv formats will be validated for specificityfunctionality and in vitro diagnostics including flow cytometry and immunohistochemistrySuccessful completion of this work will provide validated reagents for in vivo use in dogs with cancerenabling exploration of combination approaches and correlative biomarkers of response in a clinically relevant large animal cancer modelIn additionthis work will provide parallel promising immunotherapeutics for the veterinary market